JAMA Network Home
Sign In
Viewpoint

In (Faint) Praise of Pharmaceutical Import Tariffs

JAMA 10.1001/jama.2025.12207

August 11, 2025 at 11:00 AM EDT

Read the full article

This Viewpoint discusses the reasons that drug manufacturing is leaving the US; highlights the weaknesses of tariffs as currently implemented for bringing it back; and calls for the moderate implementation of tariffs as one component of industrial policy and the reinvestment of tariff revenues in pharmaceutical innovation.

Corresponding Author: James C. Robinson, PhD, School of Public Health, University of California, Berkeley, Berkeley Way West, Room 5423, Berkeley, CA 94720-7360 (James.robinson@berkeley.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.12207?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=081125

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks